Table 3.

Secondary Efficacy Endpoints in Patients Administered Macitentan 10 mg

	Baseline (n=9)	Week 24 (n=6)B	Change (n=6)
6MWD (m)	341.8±84.9	389.3±111.9	44.3±46.8
Borg dyspnea index	5.4±2.2	5.5±2.3	0.2±1.9
WHO functional classA
No. patients	9	5	–
I	0	0	–
II	4 (44.4%)	3 (60.0%)	–
III	5 (55.6%)	2 (40.0%)	–
IV	0	0	–

Unless indicated otherwise, data are expressed as the mean±SD or n (%). ^ACategorical analysis of World Health Organization (WHO) functional class was performed as a post hoc analysis. ^BWeek 24 (141–252 days), data from 6 patients who underwent both assessments during this period were used for the calculation. 6MWD, 6-minute walk distance.